<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[SINOVAC Biotech Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=40970></link><description><![CDATA[SINOVAC Biotech Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 19 Apr 2026 07:16:49 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2025/06/12_31017998_20250619083513_4115529387.png]]></url></image><language>ko-KR</language><item><title><![CDATA[SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1027431</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial a...]]></description><pubDate>Fri, 23 Jan 2026 08:30:16 +0900</pubDate></item><item><title><![CDATA[SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1026392</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants L...]]></description><pubDate>Mon, 05 Jan 2026 09:06:41 +0900</pubDate></item><item><title><![CDATA[Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1026390</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listin...]]></description><pubDate>Mon, 05 Jan 2026 08:54:28 +0900</pubDate></item><item><title><![CDATA[Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1025606</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Bo...]]></description><pubDate>Thu, 18 Dec 2025 08:53:53 +0900</pubDate></item><item><title><![CDATA[Newly Elected Directors of Sinovac Hold the First Board Meeting]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1014780</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan ...]]></description><pubDate>Fri, 11 Jul 2025 10:50:00 +0900</pubDate></item><item><title><![CDATA[SINOVAC Announces New Board Member]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1013380</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nom...]]></description><pubDate>Thu, 19 Jun 2025 08:42:24 +0900</pubDate></item><item><title><![CDATA[SINOVAC Announces Record and Distribution Dates for Special Cash Dividend]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1010438</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, E...]]></description><pubDate>Wed, 30 Apr 2025 15:41:46 +0900</pubDate></item><item><title><![CDATA[SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1010335</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legit...]]></description><pubDate>Tue, 29 Apr 2025 17:10:29 +0900</pubDate></item><item><title><![CDATA[SINOVAC Announces Decision to Declare Cash Dividend]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1008571</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”) has decided to declare a special cash dividend of US$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend from available cash re...]]></description><pubDate>Tue, 01 Apr 2025 13:54:55 +0900</pubDate></item><item><title><![CDATA[SINOVAC Announces New Board Member and Chairman of the Audit Committee]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1008402</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under...]]></description><pubDate>Sun, 30 Mar 2025 11:33:51 +0900</pubDate></item><item><title><![CDATA[SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1006684</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, th...]]></description><pubDate>Mon, 03 Mar 2025 10:40:00 +0900</pubDate></item><item><title><![CDATA[SINOVAC Issues Statement Regarding Privy Council Judgment]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1004523</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Boar...]]></description><pubDate>Fri, 17 Jan 2025 08:47:56 +0900</pubDate></item><item><title><![CDATA[SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1003091</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet...]]></description><pubDate>Wed, 18 Dec 2024 13:40:00 +0900</pubDate></item><item><title><![CDATA[시노백, 수족구병에 대한 2가 백신 제3상 임상시험 시작]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1003092</link><description><![CDATA[베이징, 중국--(Business Wire/뉴스와이어)--중국의 선도적인 바이오 의약품 공급업체인 시노백 바이오텍(Sinovac Biotech Ltd.)(이하 시노백 또는 회사)(나스닥: SVA)이 16일(현지 시간) 장바이러스 71(EV71)과 콕사키바이러스 16(CA16) 모두에 의한 수족구병(HFMD)을 예방하기 위한 백신 후보에 대한 제3상 임상시험 등록을 시작했다고 밝혔다. 아직까지 HFMD에 대한 다가 백신은 전 세계적으로 시판이 승인된 사례가...]]></description><pubDate>Wed, 18 Dec 2024 13:40:00 +0900</pubDate></item><item><title><![CDATA[Sinovac Amends Shareholder Rights Plan]]></title><link>https://www.newswire.co.kr/newsRead.php?no=984610</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.  About SINOVAC  Sinovac Biotech Ltd. (S...]]></description><pubDate>Wed, 21 Feb 2024 17:25:08 +0900</pubDate></item><item><title><![CDATA[Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=982920</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the “Board of Directors”) unanimously determined that the partial tender offer (the “Tender Offer”) by Alternative Liquidity Index LP (“Alternative Liquidity”) to acquire up to 1...]]></description><pubDate>Fri, 19 Jan 2024 15:00:00 +0900</pubDate></item><item><title><![CDATA[시노백 이사회, 만장일치로 공개매수 제안 거부]]></title><link>https://www.newswire.co.kr/newsRead.php?no=982921</link><description><![CDATA[베이징--(Business Wire/뉴스와이어)--중국의 선도적 생체의약품 공급업체인 시노백 바이오텍(Sinovac Biotech Ltd.)(나스닥: SVA)(시노백 또는 회사)은 자사의 이사회(이사회)가 만장일치로 결정한 사항을 오늘 발표했다. 즉, 얼터너티브 리퀴디티 인덱스(Alternative Liquidity, 이하 ‘얼터너티브 리퀴디티’)가 시노백의 보통주 최대 1000만주(주식)를 주당 현금 0.03달러(제안 가격)에 인수하는 부분 공개매수...]]></description><pubDate>Fri, 19 Jan 2024 15:00:00 +0900</pubDate></item><item><title><![CDATA[SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection]]></title><link>https://www.newswire.co.kr/newsRead.php?no=974127</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II ...]]></description><pubDate>Tue, 12 Sep 2023 10:20:00 +0900</pubDate></item><item><title><![CDATA[시노백, 항코로나19 항체 SA55 주사제 임상시험 진행 상황 보고]]></title><link>https://www.newswire.co.kr/newsRead.php?no=974128</link><description><![CDATA[베이징--(Business Wire/뉴스와이어)--중국의 선도적 바이오 의약품 공급업체인 시노백 바이오텍(Sinovac Biotech Ltd.)(시노백 또는 회사)(나스닥: SVA)은 광범위 중화 항체(neutralizing antibody) 제품인 항코로나19 항체 SA55 주사제(Anti-COVID-19 Antibody SA55 Injection)(SA55 주사제)의 임상 1상 시험을 베이징에서 완료했고, 최근 첫 번째 참가자를 성공적으로 등록한 후 상하이에서 임상 2상 시험에 ...]]></description><pubDate>Tue, 12 Sep 2023 10:20:00 +0900</pubDate></item><item><title><![CDATA[Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=973735</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the “Board of Directors”) unanimously determined that the partial tender offer (the “Tender Offer”) by Alternative Liquidity Index LP (“Alternative Liquidity”) to acquire up to 1...]]></description><pubDate>Wed, 06 Sep 2023 13:45:00 +0900</pubDate></item><item><title><![CDATA[시노백 이사회, 부분 공개매수 제안 만장일치로 거부]]></title><link>https://www.newswire.co.kr/newsRead.php?no=973736</link><description><![CDATA[베이징--(Business Wire/뉴스와이어)--중국의 선도적 바이오 의약품 공급업체인 시노백 바이오텍(Sinovac Biotech Ltd.)(나스닥: SVA)(이하 시노백 또는 회사)은 자사 이사회가 시노백 보통주 최대 1000만주(주식)를 주당 0.03달러의 현금(제안 가격)으로 인수하는 얼터너티브 리퀴디티 인덱스(Alternative Liquidity Index LP)(얼터너티브 리퀴디티)의 부분 공개매수(이하 공개매수)가 바람직하지 않으며 회사 ...]]></description><pubDate>Wed, 06 Sep 2023 13:45:00 +0900</pubDate></item><item><title><![CDATA[Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=973229</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s...]]></description><pubDate>Wed, 30 Aug 2023 13:45:00 +0900</pubDate></item><item><title><![CDATA[시노백, 민간 부분 공개매수 제안 접수 확인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=973230</link><description><![CDATA[베이징--(Business Wire/뉴스와이어)--중국의 선도적 바이오 의약품 공급업체인 시노백 바이오텍(Sinovac Biotech Ltd.)(나스닥: SVA)(이하 시노백 또는 회사)은 얼터너티브 리퀴디티 인덱스 LP(Alternative Liquidity Index LP)로부터 회사 발행 주식의 약 10.05%에 해당하는 최대 1000만주를 주당 0.03달러에 현금으로 매입하겠다는 공개매수 제안을 접수한 사실을 오늘 확인했다.  시노백 이사회는 공개매수 ...]]></description><pubDate>Wed, 30 Aug 2023 13:45:00 +0900</pubDate></item><item><title><![CDATA[Sinovac Announces Change of Legal Representative of Sinovac Beijing]]></title><link>https://www.newswire.co.kr/newsRead.php?no=973093</link><description><![CDATA[BEIJING--(Business Wire/Korea Newswire)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“Sinovac Beijing”), has changed its legal representative to Mr. Weidong Yin, the Company’s Chairman, President and Chief Executive Officer.  The Admi...]]></description><pubDate>Tue, 29 Aug 2023 09:45:00 +0900</pubDate></item><item><title><![CDATA[시노백, 시노백 베이징의 법적 대표 변경 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=973094</link><description><![CDATA[베이징--(Business Wire/뉴스와이어)--중국의 선도적인 바이오 의약품 공급업체인 시노백 바이오테크(Sinovac Biotech Ltd., 이하 시노백 또는 회사)(나스닥: SVA)가 자회사인 시노백 바이오테크(Sinovac Biotech Co., Ltd.)의 법적 대표를 회사의 회장이자 사장 겸 CEO인 웨이동 인(Weidong Yin)으로 변경했음을 발표했다.  베이징 하이뎬 구의 시장감독관리국은 산둥성 즈보시 장뎬구 인민법원의 판결 집행 명...]]></description><pubDate>Tue, 29 Aug 2023 09:45:00 +0900</pubDate></item></channel></rss>